Results 31 to 40 of about 15,278 (270)

Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori

Gut and Liver, 2021
Background/Aims: Favorable outcomes of potassium-competitive acid blocker (PCAB)-containing eradication therapy have been reported. In fact, tegoprazan, a recently developed PCAB, was presumed to show good eradication efficacy even for resistant ...
Jung Won Lee, Nayoung Kim, Ryoung Hee Nam, Jeong Eun Yu, Joo Hee Son, Sun Min Lee, Dong Ho Lee   +6 more
doaj   +1 more source

Correction: Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment [PDF]

BMC Gastroenterology
Peiwen Dong, Lin Lin, Kaidi Sun, Feng Tang, Qian Li, Xinxu Zhou, Fuli Liu, Zhilin Yang, Jiao Li, Lin Jiang, Ping Zhao, Xiaobin Sun, Qiong Wang   +12 more
doaj   +2 more sources

Diclofenac Prolongs Repolarization in Ventricular Muscle with Impaired Repolarization Reserve [PDF]

, 2012
Background: The aim of the present work was to characterize the electrophysiological effects of the non-steroidal anti- inflammatory drug diclofenac and to study the possible proarrhythmic potency of the drug in ventricular muscle.
A Farkas, A Peretz, A Varró, A Varró, A Varró, AJ Batey, Andrea Barbuti, András Varró, Attila Kristóf, B Girennavar, B Scheidel, C Bombardier, C Lengyel, C Lengyel, CL Lawrence, Cs Lengyel, D Corrado, DM Roden, DM Roden, DM Roden, E Coraboeuf, EL Fosbøl, FI Al-Jenoobi, G Hart, HA Bird, István Baczkó, István Koncz, JH Lin, JJ Duncan, Julius Gy Papp, L Carlsson, L Virág, LI Brueggemann, LL von Moltke, LY Liu, László Virág, M Hidaka, M Niemi, MA Vos, N Jost, Norbert Jost, OV Yarishkin, P McGettigan, PG Volders, Péter Biliczki, R Bort, R Varkevisser, S Trelle, T Christ, Tamás Szél, Viktor Juhász, WF Huang, WF Huang, XW Fei, Y Lu, Zoltán Husti, Zsófia Kohajda   +56 more
core   +7 more sources

The role of vonoprazan in patients with erosive esophagitis

Therapeutic Advances in Gastroenterology, 2022
Acid suppression is the primary therapy for erosive esophagitis (EE). Although proton pump inhibitors (PPIs) are considered as the first-line medication for EE, 10–20% of patients with Los Angeles C and D grade EE do not gain complete mucosal healing and
Mengyu Zhang, Yinglian Xiao, Minhu Chen
doaj   +1 more source

Antibiotic susceptibility, heteroresistance, and updated treatment strategies in helicobacter pylori infection [PDF]

, 2017
In this review, we discuss the problem of antibiotic resistance, heteroresistance, the utility of cultures and antibiotic susceptibility tests in Helicobacter pylori (Hp) eradication, as well as the updated treatment strategies for this infection.
De Angelis, Massimiliano, Mascellino, Maria Teresa, Oliva, Alessandra, Porowska, Barbara   +3 more
core   +1 more source

Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study

Gut and Liver, 2023
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough.
Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Choi, Seokuee Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, Kyun-Seop Bae   +9 more
doaj   +1 more source

A combined clinical and biomarker approach to predict diuretic response in acute heart failure [PDF]

, 2015
Background: Poor diuretic response in acute heart failure is related to poor clinical outcome. The underlying mechanisms and pathophysiology behind diuretic resistance are incompletely understood.
Bloomfield, Daniel M., Bruno, Noemi, Cleland, John G.F., Cotter, Gad, Damman, Kevin, Davison, Beth, Dittrich, Howard C., Givertz, Michael M., Hillege, Hans L., Metra, Marco, O’Connor, Christopher M., Ponikowski, Piotr, Teerlink, John R., ter Maaten, Jozine M., Valente, Mattia A.E., van Veldhuisen, Dirk J., Voors, Adriaan A.   +16 more
core   +4 more sources

Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers

The Korean Journal of Gastroenterology, 2022
Proton pump inhibitors (PPIs) have several limitations to their efficacy including insufficient acid suppression, slow onset of action, and variable efficacy among patients due to CYP2C19 metabolism. Potassium-competitive acid blockers inhibit H+-K+-ATPase in a reversible and K+-competitive manner, are novel acid suppressive drugs with rapid onset of ...
openaire   +3 more sources

Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms

Trials, 2023
Background Vonoprazan results in more potent acid suppression for gastroesophageal reflux disease (GERD) than proton pump inhibitors. It has only been approved for treating erosive esophagitis in China, but 30–40% of GERD patients cannot achieve the goal
Dongke Wang, Dan Zhou, Xinghuang Liu, Zhiyue Xu, Tao Bai, Xiaohua Hou   +5 more
doaj   +1 more source

Vonoprazan - a new drug for inhibiting gastric acid secretion

Journal of Education, Health and Sport, 2022
Introduction and purpose  Vonoprazan is a potassium-competent acid blocker (P-CAB). It has the potential to be an alternative to proton pump inhibitors (PPIs) as it inhibits hydrochloric acid secretion. The mechanism of action is different than PPIs -
Kacper Niewęgłowski, Natalia Wilczek, Michał Rycharski, Julita Niewęgłowska   +3 more
doaj   +1 more source